Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Pucer, Anja ^a   Brglez, Vesna ^a   Payré, Christine ^b   Pungerčar, Jože ^a   Lambeau, Gérard ^b   Petan, Toni ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

AMP activated protein kinase; Apoptosis; Breast cancer; Carnitine palmitoyltransferase 1; Cell survival; Etomoxir; Fatty acid oxidation; Lipid droplets; Lipid signaling; Secreted phospholipase A2

Indexed keywords

BEZAFIBRATE; ETOMOXIR; FAT DROPLET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OLEIC ACID; PERILIPIN; PERILIPIN 2; PHOSPHOLIPASE A2 GROUP X; PROTEIN KINASE B; RAPAMYCIN; S 32826; UNCLASSIFIED DRUG; VARESPLADIB;

ANIMAL CELL; ARTICLE; BIOGENESIS; BREAST CANCER; CANCER CELL; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; NONHUMAN; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; ENZYME ACTIVATION; EPOXY COMPOUNDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP X PHOSPHOLIPASES A2; HUMANS; HYDROLYSIS; LIPID METABOLISM; OLEIC ACIDS; ORGANELLES; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84884621565     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-111     Document Type: Article

References (84)

1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308. 10.1016/j.ccr.2012.02.014, 3311998, 22439925.
2. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777. 10.1038/nrc2222, 17882277.
3. Zechner R, Zimmermann R, Eichmann TO, Kohlwein SD, Haemmerle G, Lass A, Madeo F. FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling. Cell Metab 2012, 15:279-291. 10.1016/j.cmet.2011.12.018, 3314979, 22405066.
4. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012, 279:2610-2623. 10.1111/j.1742-4658.2012.08644.x, 22621751.
5. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61. 10.1016/j.cell.2009.11.027, 2885975, 20079333.
6. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24:4165-4173. 10.1038/sj.onc.1208622, 15806154.
7. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013, 13:227-232. 3766957, 23446547.
8. Jeon S-M, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665. 10.1038/nature11066, 3607316, 22660331.
9. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 1807, 2011:726-734.
10. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, Kalliomäki T, Elia A, Luo X, Nadeem V, Bungard D, Yalavarthi S, Growney JD, Wakeham A, Moolani Y, Silvester J, Ten AY, Bakker W, Tsuchihara K, Berger SL, Hill RP, Jones RG, Tsao M, Robinson MO, Thompson CB, Pan G, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011, 25:1041-1051. 10.1101/gad.1987211, 3093120, 21576264.
11. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011, 111:6130-6185. 10.1021/cr200085w, 3196595, 21910409.
12. Murakami M, Taketomi Y, Sato H, Yamamoto K. Secreted phospholipase A2 revisited. J Biochem 2011, 150:233-255. 10.1093/jb/mvr088, 21746768.
13. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, Sadilek M, Nguyen E, Lazdunski M, Lambeau G, Gelb MH. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002, 277:48535-48549. 10.1074/jbc.M205855200, 12359733.
14. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008, 77:495-520. 10.1146/annurev.biochem.76.062405.154007, 18405237.
15. Murakami M, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: an update. Biochimie 2013, 95:43-50. 10.1016/j.biochi.2012.09.007, 23022039.
16. Mounier CM, Wendum D, Greenspan E, Fléjou J-F, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 2008, 98:587-595. 10.1038/sj.bjc.6604184, 2243149, 18212756.
17. Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, de Souza P, Dong Q, Graham GG, Russell PJ. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010, 92:601-610. 10.1016/j.biochi.2010.03.019, 20362028.
18. Sved P, Scott KF, McLeod D, King NJC, Singh J, Tsatralis T, Nikolov B, Boulas J, Nallan L, Gelb MH, Sajinovic M, Graham GG, Russell PJ, Dong Q. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004, 64:6934-6940. 10.1158/0008-5472.CAN-03-3018, 15466184.
19. Mauchley D, Meng X, Johnson T, Fullerton DA, Weyant MJ. Modulation of growth in human esophageal adenocarcinoma cells by group IIA secretory phospholipase A2. J Thorac Cardiovasc Surg 2010, 139:591-599. 10.1016/j.jtcvs.2009.10.061, 20176206.
20. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 2008, 68:4277-4286. 10.1158/0008-5472.CAN-07-6517, 18519687.
21. Fijneman RJA, Bade LK, Peham JR, van de Wiel MA, van Hinsbergh VWM, Meijer GA, O'Sullivan MG, Cormier RT. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell Oncol 2009, 31:345-356.
22. Belinsky GS, Rajan TV, Saria EA, Giardina C, Rosenberg DW. Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog 2007, 46:106-116. 10.1002/mc.20271, 17091473.
23. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193. 10.1038/nrc2809, 2898136, 20168319.
24. Morioka Y, Ikeda M, Saiga A, Fujii N, Ishimoto Y, Arita H, Hanasaki K. Potential role of group X secretory phospholipase A2 in cyclooxygenase-2-dependent PGE2 formation during colon tumorigenesis. FEBS Lett 2000, 487:262-266. 10.1016/S0014-5793(00)02350-4, 11150521.
25. Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2. J Biol Chem 2005, 280:24987-24998. 10.1074/jbc.M502088200, 15863501.
26. Surrel F, Jemel I, Boilard E, Bollinger JG, Payré C, Mounier CM, Talvinen KA, Laine VJO, Nevalainen TJ, Gelb MH, Lambeau G. Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. Mol Pharmacol 2009, 76:778-790. 10.1124/mol.108.053371, 2769042, 19602573.
27. Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res 2000, 60:6353-6358.
28. Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J Biol Chem 2003, 278:31861-31870. 10.1074/jbc.M300190200, 12805375.
29. Prentki M, Madiraju SRM. Glycerolipid metabolism and signaling in health and disease. Endocr Rev 2008, 29:647-676. 10.1210/er.2008-0007, 18606873.
30. Brasaemle DL, Wolins NE. Packaging of fat: an evolving model of lipid droplet assembly and expansion. J Biol Chem 2012, 287:2273-2279. 10.1074/jbc.R111.309088, 3268387, 22090029.
31. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan Q-W, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 2011, 121:2102-2110. 10.1172/JCI46069, 3104768, 21633178.
32. Shridas P, Bailey WM, Boyanovsky BB, Oslund RC, Gelb MH, Webb NR. Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands. J Biol Chem 2010, 285:20031-20039. 10.1074/jbc.M109.090423, 2888415, 20421306.
33. Sato H, Isogai Y, Masuda S, Taketomi Y, Miki Y, Kamei D, Hara S, Kobayashi T, Ishikawa Y, Ishii T, Ikeda K, Taguchi R, Ishimoto Y, Suzuki N, Yokota Y, Hanasaki K, Suzuki-Yamamoto T, Yamamoto K, Murakami M. Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function. J Biol Chem 2011, 286:11632-11648. 10.1074/jbc.M110.206755, 3064216, 21266581.
34. Li X, Shridas P, Forrest K, Bailey W, Webb NR. Group X secretory phospholipase A2 negatively regulates adipogenesis in murine models. FASEB J 2010, 24:4313-4324. 10.1096/fj.10-154716, 2974424, 20585029.
35. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VCJ, Laurent G, Adams AC, Sundvall M, Song SJ, Ito K, Finley LS, Egia A, Libermann T, Gerhart-Hines Z, Puigserver P, Haigis MC, Maratos-Flier E, Richardson AL, Schafer ZT, Pandolfi PP. A metabolic prosurvival role for PML in breast cancer. J Clin Invest 2012, 122:3088-3100. 10.1172/JCI62129, 3433768, 22886304.
36. Mannello F, Qin W, Zhu W, Fabbri L, Tonti GA, Sauter ER. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIA secretory phospholipase A2. Breast Cancer Res Treat 2008, 111:209-218. 10.1007/s10549-007-9779-1, 17932742.
37. Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010-present). Expert Opin Ther Pat 2013, 23:333-344. 10.1517/13543776.2013.754425, 23294257.
38. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol 2010, 21:473-480. 10.1097/MOL.0b013e32833eb581, 20739882.
39. Jemel I, Ii H, Oslund RC, Payré C, Dabert-Gay A-S, Douguet D, Chargui K, Scarzello S, Gelb MH, Lambeau G. Group X secreted phospholipase A2 proenzyme is matured by a furin-like proprotein convertase and releases arachidonic acid inside of human HEK293 cells. J Biol Chem 2011, 286:36509-36521. 10.1074/jbc.M111.268540, 3196088, 21878635.
40. Eerola LI, Surrel F, Nevalainen TJ, Gelb MH, Lambeau G, Laine VJO. Analysis of expression of secreted phospholipases A2 in mouse tissues at protein and mRNA levels. Biochim Biophys Acta 2006, 1761:745-756. 10.1016/j.bbalip.2006.04.002, 16757211.
41. Dória ML, Cotrim CZ, Simões C, Macedo B, Domingues P, Domingues MR, Helguero LA. Lipidomic analysis of phospholipids from human mammary epithelial and breast cancer cell lines. J Cell Physiol 2013, 228:457-468. 10.1002/jcp.24152, 22767159.
42. Przybytkowski E, Joly E, Nolan CJ, Hardy S, Francoeur A-M, Langelier Y, Prentki M. Upregulation of cellular triacylglycerol - free fatty acid cycling by oleate is associated with long-term serum-free survival of human breast cancer cells. Biochem Cell Biol 2007, 85:301-310. 10.1139/O07-001, 17612624.
43. Pruzanski W, Lambeau L, Lazdunsky M, Cho W, Kopilov J, Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta 2005, 1736:38-50.
44. Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat 2010, 122:661-670. 10.1007/s10549-009-0594-8, 19851860.
45. Bezzine S, Koduri RS, Valentin E, Murakami M, Kudo I, Ghomashchi F, Sadilek M, Lambeau G, Gelb MH. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J Biol Chem 2000, 275:3179-3191. 10.1074/jbc.275.5.3179, 10652303.
46. Petan T, Križaj I, Gelb MH, Pungerčar J. Ammodytoxins, potent presynaptic neurotoxins, are also highly efficient phospholipase A2 enzymes. Biochemistry 2005, 44:12535-12545. 10.1021/bi051024r, 16156665.
47. Hardy S, St-Onge GG, Joly E, Langelier Y, Prentki M. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J Biol Chem 2005, 280:13285-13291. 10.1074/jbc.M410922200, 15695516.
48. Connolly S, Bennion C, Botterell S, Croshaw PJ, Hallam C, Hardy K, Hartopp P, Jackson CG, King SJ, Lawrence L, Mete A, Murray D, Robinson DH, Smith GM, Stein L, Walters I, Wells E, Withnall WJ. Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton. J Med Chem 2002, 45:1348-1362. 10.1021/jm011050x, 11882004.
49. Wen Z-H, Su Y-C, Lai P-L, Zhang Y, Xu Y-F, Zhao A, Yao G-Y, Jia C-H, Lin J, Xu S, Wang L, Wang X-K, Liu A-L, Jiang Y, Dai Y-F, Bai X-C. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. Oncogene 2013, 32:160-170. 10.1038/onc.2012.47, 22349822.
50. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 2011, 89:221-228. 10.1007/s00109-011-0726-6, 21301797.
51. Ferry G, Moulharat N, Pradère J-P, Desos P, Try A, Genton A, Giganti A, Beucher-Gaudin M, Lonchampt M, Bertrand M, Saulnier-Blache J-S, Tucker GC, Cordi A, Boutin JA. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 2008, 327:809-819. 10.1124/jpet.108.141911, 18755937.
52. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G, Prestwich GD. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009, 69:5441-5449. 10.1158/0008-5472.CAN-09-0302, 3446773, 19509223.
53. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010, 120:142-156. 10.1172/JCI38942, 2799198, 20038799.
54. Ceccarelli SM, Chomienne O, Gubler M, Arduini A. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research. J Med Chem 2011, 54:3109-3152. 10.1021/jm100809g, 21504156.
55. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV, Ory DS, Schaffer JE. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003, 100:3077-3082. 10.1073/pnas.0630588100, 152249, 12629214.
56. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012, 12:181-195. 3322353, 22318237.
57. Olofsson S-O, Boström P, Andersson L, Rutberg M, Perman J, Borén J. Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta 2009, 1791:448-458. 10.1016/j.bbalip.2008.08.001, 18775796.
58. Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis 2010, 33:469-477. 10.1007/s10545-010-9061-2, 2950079, 20195903.
59. Bickel PE, Tansey JT, Welte MA. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 2009, 1791:419-440. 10.1016/j.bbalip.2009.04.002, 2782626, 19375517.
60. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011, 17:1498-1503. 10.1038/nm.2492, 22037646.
61. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012, 13:251-262. 10.1038/nrm3311, 22436748.
62. Ahmadian M, Abbott MJ, Tang T, Hudak CSS, Kim Y, Bruss M, Hellerstein MK, Lee H-Y, Samuel VT, Shulman GI, Wang Y, Duncan RE, Kang C, Sul HS. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab 2011, 13:739-748. 10.1016/j.cmet.2011.05.002, 3148136, 21641555.
63. Wendel AA, Lewin TM, Coleman RA. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta 2009, 1791:501-506. 10.1016/j.bbalip.2008.10.010, 2737689, 19038363.
64. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, De Schrijver E, Van de Sande T, Noël A, Foufelle F, Verhoeven G. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005, 65:2441-2448. 10.1158/0008-5472.CAN-04-3025, 15781660.
65. Zhang Y, Lemasters J, Herman B. Secretory group IIA phospholipase A2 generates anti-apoptotic survival signals in kidney fibroblasts. J Biol Chem 1999, 274:27726-27733. 10.1074/jbc.274.39.27726, 10488115.
66. Masuda S, Yamamoto K, Hirabayashi T, Ishikawa Y, Ishii T, Kudo I, Murakami M. Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. Biochem J 2008, 409:429-438. 10.1042/BJ20070844, 17868035.
67. Arioka M, Cheon S-H, Ikeno Y, Nakashima S, Kitamoto K. A novel neurotrophic role of secretory phospholipases A2 for cerebellar granule neurons. FEBS Lett 2005, 579:2693-2701. 10.1016/j.febslet.2005.03.092, 15862311.
68. Fonteh AN, Marion CR, Barham BJ, Edens MB, Atsumi G, Samet JM, High KP, Chilton FH. Enhancement of mast cell survival: a novel function of some secretory phospholipase A2 isotypes. J Immunol 2001, 167:4161-4171.
69. Saegusa J, Akakura N, Wu C-Y, Hoogland C, Ma Z, Lam KS, Liu F-T, Takada YK, Takada Y. Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem 2008, 283:26107-26115. 10.1074/jbc.M804835200, 2533795, 18635536.
70. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, Holowka DA, Cerione RA. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A 2011, 108:4852-4857. 10.1073/pnas.1017667108, 3064359, 21368175.
71. Nelson J, Gibbons E, Pickett KR, Streeter M, Warcup AO, Yeung CH-Y, Judd AM, Bell JD. Relationship between membrane permeability and specificity of human secretory phospholipase A2 isoforms during cell death. Biochim Biophys Acta 1808, 2011:1913-1920.
72. Henique C, Mansouri A, Fumey G, Lenoir V, Girard J, Bouillaud F, Prip-Buus C, Cohen I. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J Biol Chem 2010, 285:36818-36827. 10.1074/jbc.M110.170431, 2978610, 20837491.
73. Guijas C, Pérez-Chacón G, Astudillo AM, Rubio JM, Gil-de-Gómez L, Balboa MA, Balsinde J. Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A2-dependent synthesis of lipid droplets in human monocytes. J Lipid Res 2012, 53:2343-2354. 10.1194/jlr.M028423, 22949356.
74. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FPW, Preiss-Landl K, Kolbe T, Rülicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 2011, 17:1076-1085. 10.1038/nm.2439, 3244833, 21857651.
75. Mottillo EP, Bloch AE, Leff T, Granneman JG. Lipolytic products activate peroxisome proliferator-activated receptor (PPAR) α and δ in brown adipocytes to match fatty acid oxidation with supply. J Biol Chem 2012, 287:25038-25048. 10.1074/jbc.M112.374041, 3408177, 22685301.
76. Boren J, Brindle KM. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ 2012, 19:1561-1570. 10.1038/cdd.2012.34, 3422477, 22460322.
77. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009, 9:307. 10.1186/1471-2407-9-307, 2744705, 19723334.
78. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013, 17:113-124. 10.1016/j.cmet.2012.12.001, 23274086.
79. Hardie DG. The LKB1-AMPK pathway-friend or foe in cancer?. Cancer Cell 2013, 23:131-132. 10.1016/j.ccr.2013.01.009, 23410967.
80. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY-J, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011, 13:376-388. 10.1016/j.cmet.2011.03.009, 3086578, 21459323.
81. Rouault M, Le Calvez C, Boilard E, Surrel F, Singer A, Ghomashchi F, Bezzine S, Scarzello S, Bollinger J, Gelb MH, Lambeau G. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry 2007, 46:1647-1662. 10.1021/bi062119b, 17279628.
82. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007, 8:R19. 10.1186/gb-2007-8-2-r19, 1852402, 17291332.
83. Cupillard L, Koumanov K, Mattéi MG, Lazdunski M, Lambeau G. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem 1997, 272:15745-15752. 10.1074/jbc.272.25.15745, 9188469.
84. Wlodkowic D, Skommer J, Pelkonen J. Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. Leuk Res 2007, 31:1687-1700. 10.1016/j.leukres.2007.03.008, 17428536.